KB-1089

Lifastuzumab

52648

Home » Lifastuzumab

Background of Lifastuzumab

NaPi2B is a multi-transmembrane type II sodium-dependent phosphate transporter within the SLC34 solute carrier family. It functions in the transport of inorganic phosphate transcellularly and plays a role in phosphate homeostasis. Normally, it is expressed on the apical surfaces of epithelial cells, including type II pneumocytes in the lung, intestinal epithelium, and epithelial lining of the uterus and fallopian tubes. Lifastuzumab vedotin (LIFA, or DNIB0600A), is an anti-NaPi2B ADC utilizing a humanized IgG1 conjugated to an MMAE payload via a cleavable valine-citrulline linker.

Specifications

Catalog Number	KB-1089
Antibody Name	Lifastuzumab
Isotype	Human IgG1,kappa
FC Muations	WT
Target	SLC34A2
Species Reactivity	Human
Host Cell Line	EXPI CHO
Purification Method	Affinity purified
Concentration	>2 mg/mL
Formulation	50 mM sodium citrate,150mM NaCl,pH5.5
Purity	>95% by SDS-PAGE and SEC-HPLC
Validation	FACS
Endotoxin Level	<0.2 EU/mg as determined by the LAL method
Sterility	0.2μm filtered
Storage	It is recommended that the protein should be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
Stability	Stable for twelve months from date of receipt when stored at -20°C to -80°C; Stored at 2-8°C for one month without detectable loss of activity.

Characterization

Application

References

Banerjee S, et al. Anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) compared with pegylated liposomal doxorubicin in patients with platinumresistant ovarian cancer in a randomized, open-label, phase II study. Ann Oncol. 2018 Apr 1;29(4):917-923.
Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68(4):284–96.